Use of integrated SPECT/CT imaging for tumor dosimetry in I-131 radioimmunotherapy: a pilot patient study.
about
Prediction of therapy tumor-absorbed dose estimates in I-131 radioimmunotherapy using tracer data via a mixed-model fit to time activityFactors affecting the stability and repeatability of gamma camera calibration for quantitative imaging applications based on a retrospective review of clinical dataRegularized reconstruction in quantitative SPECT using CT side information from hybrid imaging.VIDA: a voxel-based dosimetry method for targeted radionuclide therapy using Geant4.Comparison of I-131 radioimmunotherapy tumor dosimetry: unit density sphere model versus patient-specific Monte Carlo calculations131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modelingBio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin's lymphoma.MIRD pamphlet No. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapyRadiolabeled liposome imaging determines an indication for liposomal anticancer agent in ovarian cancer mouse xenograft models.Radiofrequency ablation before intratumoral injection of (131)I-chTNT improves the tumor-to-normal tissue ratio in solid VX2 tumor.MIRD pamphlet No. 24: Guidelines for quantitative 131I SPECT in dosimetry applications.Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications.I-131 tositumomab.Methodology to incorporate biologically effective dose and equivalent uniform dose in patient-specific 3-dimensional dosimetry for non-Hodgkin lymphoma patients targeted with 131I-tositumomab therapy.Spatial resolution and image qualities of Zr-89 on Siemens Biograph TruePoint PET/CT.Practical Nuclear Medicine and Utility of Phantoms for Internal Dosimetry: XCAT Compared with Zubal.
P2860
Q30561088-19443DDA-CE5F-43D6-8B4C-ECA055FF29D7Q30977013-18CAA626-8859-4EA3-AFD8-986744E2CAFEQ33930006-DBA6971F-E826-4B7F-A7C9-1A8A0B659118Q35067264-49AADBF6-9410-47A9-BAD3-78520A851F8CQ35288449-5E96CD3E-E0FA-42A7-9C2C-7D889CF498CDQ35825755-2F862EE2-FA86-4414-865C-8FC0A4812A0BQ35851824-DEC6E075-09F0-45F9-A3E9-A0876C732712Q36302205-C53BBD66-CAC2-4F7D-BF3B-48866E341987Q36495946-ABBDEC76-0957-4F6B-AFBA-09BB3E7B1198Q37323292-6C34416D-DFA2-41EF-B89B-5C6DA53796DAQ37675439-A838C1E6-DA07-4E35-B908-9ABC42F18C03Q37752447-3457E33E-760B-4F86-A42E-9B7796AB79D2Q37768797-3EA8BA85-255E-4512-A7D9-3A880D3D2D52Q42038270-73746E8C-AFC4-4635-B5E7-02B08E3099A4Q42555525-B53B3AA6-811A-46DF-BAE2-B95C2F92BE96Q51309489-D7C29636-B24E-4738-A106-C7D1C532C397
P2860
Use of integrated SPECT/CT imaging for tumor dosimetry in I-131 radioimmunotherapy: a pilot patient study.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Use of integrated SPECT/CT ima ...... herapy: a pilot patient study.
@ast
Use of integrated SPECT/CT ima ...... herapy: a pilot patient study.
@en
type
label
Use of integrated SPECT/CT ima ...... herapy: a pilot patient study.
@ast
Use of integrated SPECT/CT ima ...... herapy: a pilot patient study.
@en
prefLabel
Use of integrated SPECT/CT ima ...... herapy: a pilot patient study.
@ast
Use of integrated SPECT/CT ima ...... herapy: a pilot patient study.
@en
P2093
P2860
P356
P1476
Use of integrated SPECT/CT ima ...... herapy: a pilot patient study.
@en
P2093
Anca M Avram
Kenneth F Koral
Mark S Kaminski
Scott J Wilderman
Yuni K Dewaraja
P2860
P304
P356
10.1089/CBR.2008.0568
P577
2009-08-01T00:00:00Z